FibroGen (FGEN) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

FGEN Stock Forecast

FibroGen stock forecast is as follows: an average price target of $28.00 (represents a 7900.00% upside from FGEN’s last price of $0.35) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.

FGEN Price Target

The average price target for FibroGen (FGEN) is $28.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $28.00 to $28.00. This represents a potential 7900.00% upside from FGEN's last price of $0.35.

FGEN Analyst Ratings

Buy

According to 2 Wall Street analysts, FibroGen's rating consensus is 'Buy'. The analyst rating breakdown for FGEN stock is 0 'Strong Buy' (0.00%), 1 'Buy' (50.00%), 1 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

FibroGen Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Jun 02, 2023	Annabel Samimy	Stifel Nicolaus	$28.00	$17.32	61.66%	7900.00%

Row per page

Go to

The latest FibroGen stock forecast, released on Jun 02, 2023 by Annabel Samimy from Stifel Nicolaus, set a price target of $28.00, which represents a 61.66% increase from the stock price at the time of the forecast ($17.32), and a 7900.00% increase from FGEN last price ($0.35).

FibroGen Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	-
Avg Price Target	-	-	-
Last Closing Price	$0.35	$0.35	$0.35
Upside/Downside	-100.00%	-100.00%	-100.00%

In the current month, the average price target of FibroGen stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to FibroGen's last price of $0.35. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Jul 31, 2024	William Blair	Market Perform	Market Perform	Hold
Jan 30, 2023	William Blair	-	Outperform	Upgrade
Jan 05, 2023	Bank of America Securities	-	Buy	Upgrade

Row per page

Go to

FibroGen's last stock rating was published by William Blair on Jul 31, 2024. The company gave FGEN a "Market Perform" rating, the same as its previous rate.

FibroGen Financial Forecast

FibroGen Revenue Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$27.14M	$40.13M	$44.32M	$36.16M	$34.37M	$15.73M	$29.81M	$60.83M	$16.54M	$155.97M	$24.36M	$38.43M	$65.00M	$44.03M
Avg Forecast	$61.46M	$55.98M	$50.51M	$45.03M	$39.19M	$37.38M	$37.38M	$37.38M	$37.02M	$41.36M	$37.96M	$37.46M	$20.23M	$34.84M	$34.66M	$36.66M	$38.90M	$36.84M	$34.73M	$31.52M	$23.97M	$31.62M	$36.16M	$28.76M	$47.65M	$129.74M	$69.08M	$41.84M	$100.81M	$61.49M
High Forecast	$61.46M	$55.98M	$50.51M	$45.03M	$39.19M	$37.38M	$37.38M	$37.38M	$37.02M	$41.36M	$37.96M	$37.46M	$20.23M	$34.88M	$34.66M	$36.66M	$38.90M	$36.84M	$34.73M	$31.52M	$23.97M	$31.62M	$36.16M	$28.76M	$47.65M	$129.74M	$69.08M	$41.84M	$100.81M	$61.49M
Low Forecast	$61.46M	$55.98M	$50.51M	$45.03M	$39.19M	$37.38M	$37.38M	$37.38M	$37.02M	$41.36M	$37.96M	$37.46M	$20.23M	$34.80M	$34.66M	$36.66M	$38.90M	$36.84M	$34.73M	$31.52M	$23.97M	$31.62M	$36.16M	$28.76M	$47.65M	$129.74M	$69.08M	$41.84M	$100.81M	$61.49M
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	9	9
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.70%	1.09%	1.28%	1.15%	1.43%	0.50%	0.82%	2.12%	0.35%	1.20%	0.35%	0.92%	0.64%	0.72%

FibroGen's average Quarter revenue forecast for Mar 24 based on 1 analysts is $36.66M, with a low forecast of $36.66M, and a high forecast of $36.66M. FGEN's average Quarter revenue forecast represents a 35.11% increase compared to the company's last Quarter revenue of $27.14M (Dec 23).

FibroGen EBITDA Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	9	9
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-87.48M	$-63.48M	$-85.40M	$-75.06M	$-62.54M	$-91.86M	$-70.37M	$-60.41M	$-131.27M	$53.91M	$-128.98M	$-65.78M	$-52.44M	$39.37M
Avg Forecast	$-50.83M	$-46.30M	$-41.78M	$-37.25M	$-32.42M	$-30.91M	$-30.91M	$-30.91M	$-30.62M	$-34.21M	$-31.40M	$-30.99M	$-16.73M	$-28.82M	$-28.67M	$-62.02M	$-32.18M	$-30.47M	$-28.72M	$-66.34M	$-77.63M	$-27.12M	$-31.01M	$-70.95M	$-40.86M	$-111.25M	$-59.24M	$-72.59M	$-86.45M	$-52.73M
High Forecast	$-50.83M	$-46.30M	$-41.78M	$-37.25M	$-32.42M	$-30.91M	$-30.91M	$-30.91M	$-30.62M	$-34.21M	$-31.40M	$-30.99M	$-16.73M	$-28.79M	$-28.67M	$-49.62M	$-32.18M	$-30.47M	$-28.72M	$-53.07M	$-62.10M	$-27.12M	$-31.01M	$-56.76M	$-40.86M	$-111.25M	$-59.24M	$-58.07M	$-86.45M	$-52.73M
Low Forecast	$-50.83M	$-46.30M	$-41.78M	$-37.25M	$-32.42M	$-30.91M	$-30.91M	$-30.91M	$-30.62M	$-34.21M	$-31.40M	$-30.99M	$-16.73M	$-28.85M	$-28.67M	$-74.43M	$-32.18M	$-30.47M	$-28.72M	$-79.60M	$-93.16M	$-27.12M	$-31.01M	$-85.14M	$-40.86M	$-111.25M	$-59.24M	$-87.10M	$-86.45M	$-52.73M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.72%	2.08%	2.97%	1.13%	0.81%	3.39%	2.27%	0.85%	3.21%	-0.48%	2.18%	0.91%	0.61%	-0.75%

1 analysts predict FGEN's average Quarter EBITDA for Dec 21 to be $-40.86M, with a high of $-40.86M and a low of $-40.86M. This is -175.80% lower than FibroGen's previous annual EBITDA (Sep 21) of $53.91M.

FibroGen Net Income Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	9	9
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-55.44M	$-63.62M	$-87.68M	$-77.50M	$-66.45M	$-92.06M	$-73.19M	$-63.52M	$-134.42M	$49.80M	$-133.99M	$-71.75M	$-58.63M	$33.00M
Avg Forecast	$28.00M	$25.21M	$22.34M	$19.43M	$-3.25M	$-4.62M	$-6.07M	$-6.13M	$-9.05M	$-8.04M	$-11.06M	$-9.05M	$-22.11M	$-30.79M	$-32.16M	$-65.24M	$-42.72M	$-68.46M	$-70.75M	$-69.78M	$-79.29M	$-80.87M	$-92.01M	$-74.63M	$-66.18M	$-698.85K	$-48.12M	$-79.18M	$-23.36M	$-79.87M
High Forecast	$28.00M	$25.21M	$22.34M	$19.43M	$-3.25M	$-4.62M	$-6.07M	$-6.13M	$-9.05M	$-8.04M	$-11.06M	$-9.05M	$-22.11M	$-30.79M	$-32.16M	$-52.19M	$-42.72M	$-68.46M	$-70.75M	$-55.82M	$-63.43M	$-80.87M	$-92.01M	$-59.70M	$-66.18M	$-698.85K	$-48.12M	$-63.34M	$-23.36M	$-79.87M
Low Forecast	$28.00M	$25.21M	$22.34M	$19.43M	$-3.25M	$-4.62M	$-6.07M	$-6.13M	$-9.05M	$-8.04M	$-11.06M	$-9.05M	$-22.11M	$-30.79M	$-32.16M	$-78.29M	$-42.72M	$-68.46M	$-70.75M	$-83.73M	$-95.15M	$-80.87M	$-92.01M	$-89.55M	$-66.18M	$-698.85K	$-48.12M	$-95.01M	$-23.36M	$-79.87M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.30%	0.93%	1.24%	1.11%	0.84%	1.14%	0.80%	0.85%	2.03%	-71.26%	2.78%	0.91%	2.51%	-0.41%

FibroGen's average Quarter net income forecast for Dec 21 is $-66.18M, with a range of $-66.18M to $-66.18M. FGEN's average Quarter net income forecast represents a -232.89% decrease compared to the company's last Quarter net income of $49.80M (Sep 21).

FibroGen SG&A Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	9	9
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$24.22M	$25.57M	$31.18M	$34.27M	$33.97M	$29.90M	$30.26M	$30.56M	$34.74M	$25.85M	$32.55M	$30.78M	$42.25M	$-48.98M
Avg Forecast	$40.86M	$37.22M	$33.58M	$29.94M	$26.06M	$24.85M	$24.85M	$24.85M	$24.61M	$27.50M	$25.24M	$24.91M	$13.45M	$23.16M	$23.04M	$31.55M	$25.86M	$24.49M	$23.09M	$20.96M	$20.54M	$21.02M	$24.04M	$19.12M	$31.68M	$86.26M	$45.93M	$33.96M	$67.02M	$40.88M
High Forecast	$40.86M	$37.22M	$33.58M	$29.94M	$26.06M	$24.85M	$24.85M	$24.85M	$24.61M	$27.50M	$25.24M	$24.91M	$13.45M	$23.19M	$23.04M	$37.86M	$25.86M	$24.49M	$23.09M	$20.96M	$24.65M	$21.02M	$24.04M	$19.12M	$31.68M	$86.26M	$45.93M	$40.76M	$67.02M	$40.88M
Low Forecast	$40.86M	$37.22M	$33.58M	$29.94M	$26.06M	$24.85M	$24.85M	$24.85M	$24.61M	$27.50M	$25.24M	$24.91M	$13.45M	$23.14M	$23.04M	$25.24M	$25.86M	$24.49M	$23.09M	$20.96M	$16.43M	$21.02M	$24.04M	$19.12M	$31.68M	$86.26M	$45.93M	$27.17M	$67.02M	$40.88M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.94%	1.04%	1.35%	1.64%	1.65%	1.42%	1.26%	1.60%	1.10%	0.30%	0.71%	0.91%	0.63%	-1.20%

FibroGen's average Quarter SG&A projection for Mar 24 is $31.55M, based on 1 Wall Street analysts, with a range of $25.24M to $37.86M. The forecast indicates a 30.24% rise compared to FGEN last annual SG&A of $24.22M (Dec 23).

FibroGen EPS Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	9	9
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.57	$-0.65	$-0.90	$-0.82	$-0.71	$-0.98	$-0.78	$-0.68	$-1.45	$0.54	$-1.45	$-0.78	$-0.64	$0.36
Avg Forecast	$0.28	$0.25	$0.22	$0.19	$-0.03	$-0.05	$-0.06	$-0.06	$-0.09	$-0.08	$-0.11	$-0.09	$-0.22	$-0.31	$-0.32	$-0.42	$-0.42	$-0.68	$-0.70	$-0.75	$-0.94	$-0.81	$-0.92	$-0.83	$-0.66	$-0.01	$-0.48	$-0.87	$-0.23	$-0.80
High Forecast	$0.28	$0.25	$0.22	$0.19	$-0.03	$-0.05	$-0.06	$-0.06	$-0.09	$-0.08	$-0.11	$-0.09	$-0.22	$-0.31	$-0.32	$-0.42	$-0.42	$-0.68	$-0.70	$-0.75	$-0.94	$-0.81	$-0.92	$-0.83	$-0.66	$-0.01	$-0.48	$-0.87	$-0.23	$-0.80
Low Forecast	$0.28	$0.25	$0.22	$0.19	$-0.03	$-0.05	$-0.06	$-0.06	$-0.09	$-0.08	$-0.11	$-0.09	$-0.22	$-0.31	$-0.32	$-0.42	$-0.42	$-0.68	$-0.70	$-0.75	$-0.94	$-0.81	$-0.92	$-0.83	$-0.66	$-0.01	$-0.48	$-0.87	$-0.23	$-0.80
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.34%	0.95%	1.28%	1.09%	0.76%	1.21%	0.85%	0.82%	2.19%	-77.14%	3.01%	0.90%	2.74%	-0.45%

According to 1 Wall Street analysts, FibroGen's projected average Quarter EPS for Dec 21 is $-0.66, with a low estimate of $-0.66 and a high estimate of $-0.66. This represents a -222.75% decrease compared to FGEN previous annual EPS of $0.54 (Sep 21).

FibroGen Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
HEPA	Hepion Pharmaceuticals	$0.69	$70.00	10044.93%	Buy
FGEN	FibroGen	$0.35	$28.00	7900.00%	Buy
LYEL	Lyell Immunopharma	$1.11	$6.67	500.90%	Hold
GOSS	Gossamer Bio	$0.71	$3.75	428.17%	Buy
STRO	Sutro Biopharma	$2.70	$11.14	312.59%	Buy
BMEA	Biomea Fusion	$6.42	$22.75	254.36%	Buy
LRMR	Larimar Therapeutics	$6.38	$20.33	218.65%	Buy
ZURA	Zura Bio	$3.15	$10.00	217.46%	Buy
FIXX	Q32 Bio	$0.93	$2.70	190.32%	Buy
DAWN	Day One Biopharmaceuticals	$13.52	$38.80	186.98%	Buy
STOK	Stoke Therapeutics	$11.61	$30.60	163.57%	Buy
CGEM	Cullinan Oncology	$13.10	$31.50	140.46%	Buy
SNDX	Syndax Pharmaceuticals	$15.77	$34.30	117.50%	Buy
VSTM	Verastem	$3.96	$8.33	110.35%	Buy
MREO	Mereo BioPharma Group	$3.49	$6.75	93.41%	Buy
ARDX	Ardelyx	$4.79	$8.75	82.67%	Buy
MRUS	Merus	$43.49	$77.13	77.35%	Buy
BMRN	BioMarin Pharmaceutical	$61.97	$101.70	64.11%	Buy
AKRO	Akero Therapeutics	$31.03	$46.00	48.24%	Buy
PCVX	Vaxcyte	$87.08	$124.00	42.40%	Buy
BPMC	Blueprint Medicines	$94.60	$109.71	15.97%	Buy
RVMD	Revolution Medicines, Inc. Warrant	$56.47	$60.63	7.37%	Buy
AGIO	Agios Pharmaceuticals	$54.41	$48.00	-11.78%	Buy

FGEN Forecast FAQ

Is FibroGen a good buy?

Yes, according to 2 Wall Street analysts, FibroGen (FGEN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 50.00% of FGEN's total ratings.

What is FGEN's price target?

FibroGen (FGEN) average price target is $28 with a range of $28 to $28, implying a 7900.00% from its last price of $0.35. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will FibroGen stock go up soon?

According to Wall Street analysts' prediction for FGEN stock, the company can go up by 7900.00% (from the last price of $0.35 to the average price target of $28), up by 7900.00% based on the highest stock price target, and up by 7900.00% based on the lowest stock price target.

Can FibroGen stock reach $1?

FGEN's average twelve months analyst stock price target of $28 supports the claim that FibroGen can reach $1 in the near future.

What are FibroGen's analysts' financial forecasts?

FibroGen's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $151.32M (high $151.32M, low $151.32M), average EBITDA is $-125M (high $-125M, low $-125M), average net income is $-20.073M (high $-20.073M, low $-20.073M), average SG&A $100.6M (high $100.6M, low $100.6M), and average EPS is $-0.2 (high $-0.2, low $-0.2). FGEN's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $212.98M (high $212.98M, low $212.98M), average EBITDA is $-176M (high $-176M, low $-176M), average net income is $94.99M (high $94.99M, low $94.99M), average SG&A $141.6M (high $141.6M, low $141.6M), and average EPS is $0.945 (high $0.945, low $0.945).

Did the FGEN's actual financial results beat the analysts' financial forecasts?

Based on FibroGen's last annual report (Dec 2023), the company's revenue was $147.75M, beating the average analysts forecast of $141.99M by 4.06%. Apple's EBITDA was $-282M, beating the average prediction of $-158M by 78.70%. The company's net income was $-284M, beating the average estimation of $-252M by 12.92%. Apple's SG&A was $115.25M, beating the average forecast of $94.4M by 22.09%. Lastly, the company's EPS was $-2.92, beating the average prediction of $-2.563 by 13.92%. In terms of the last quarterly report (Dec 2023), FibroGen's revenue was $27.14M, missing the average analysts' forecast of $38.9M by -30.24%. The company's EBITDA was $-87.477M, beating the average prediction of $-32.175M by 171.88%. FibroGen's net income was $-55.436M, beating the average estimation of $-42.719M by 29.77%. The company's SG&A was $24.22M, missing the average forecast of $25.86M by -6.34%. Lastly, the company's EPS was $-0.57, beating the average prediction of $-0.425 by 34.12%